Show simple item record

The effects of treatment on peripheral blood immune cell profile in pancreatic ductal adenocarcinoma (PDAC)

dc.contributor.authorTulytė, Skaistė
dc.contributor.authorCharaciejus, Dainius
dc.contributor.authorMatuzevičienė, Rėda
dc.contributor.authorVarnaitė, Aušra
dc.contributor.authorRadzevičius, Mantas
dc.contributor.authorŽvirblis, Tadas
dc.contributor.authorŠileikis, Audrius
dc.date.accessioned2023-09-18T20:52:15Z
dc.date.available2023-09-18T20:52:15Z
dc.date.issued2022
dc.identifier.issn0250-7005
dc.identifier.other(PMID)35641268
dc.identifier.urihttps://etalpykla.vilniustech.lt/handle/123456789/153312
dc.description.abstractBACKGROUND/AIM: This study evaluated whether circulating lymphocytes, assessed by flow cytometry, is a prognostic biomarker in pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: We studied T cell subsets in blood samples from a cohort of 41 patients diagnosed with PDAC. Patients underwent surgery of the primary site and adjuvant chemotherapy or were treated with 1st line chemotherapy (mFOLFIRINOX regimen or gemcitabine alone). The changes in T cell subpopulations during treatment were evaluated at the initial diagnosis before surgery, and after 2 and 4 months. Friedman test was used for statistical analysis. RESULTS: A decline in CD19+ B lymphocytes, natural killer (NK) cells CD3-CD56+CD16+, and T regulatory cells CD4+FOXP3+ during treatment was observed. NKT-like cells CD3+CD56+ and cytotoxic T cells CD3+CD8+ tended to increase after two months and decrease after that. CONCLUSION: Statistically significant changes in lymphocyte counts in peripheral blood were detected in patients with PDAC during treatment.eng
dc.formatPDF
dc.format.extentp. 3067-3073
dc.format.mediumtekstas / txt
dc.language.isoeng
dc.relation.isreferencedbyScience Citation Index Expanded (Web of Science)
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyPubMed
dc.rightsLaisvai prieinamas internete
dc.source.urihttps://talpykla.elaba.lt/elaba-fedora/objects/elaba:134703560/datastreams/MAIN/content
dc.titleThe effects of treatment on peripheral blood immune cell profile in pancreatic ductal adenocarcinoma (PDAC)
dc.typeStraipsnis Web of Science DB / Article in Web of Science DB
dcterms.licenseCreative Commons – Attribution – NonCommercial – NoDerivatives – 4.0 International
dcterms.references37
dc.type.pubtypeS1 - Straipsnis Web of Science DB / Web of Science DB article
dc.contributor.institutionVilniaus universiteto ligoninė Santaros klinikos, Hematologijos, onkologijos ir transfuziologijos centras Vilniaus universitetas
dc.contributor.institutionVilniaus universitetas
dc.contributor.institutionVilniaus Gedimino technikos universitetas Vilniaus universitetas
dc.contributor.facultyMechanikos fakultetas / Faculty of Mechanics
dc.subject.researchfieldT 009 - Mechanikos inžinerija / Mechanical enginering
dc.subject.researchfieldM 001 - Medicina / Medicine
dc.subject.vgtuprioritizedfieldsIK0303 - Dirbtinio intelekto ir sprendimų priėmimo sistemos / Artificial intelligence and decision support systems
dc.subject.ltspecializationsL105 - Sveikatos technologijos ir biotechnologijos / Health technologies and biotechnologies
dc.subject.enB lymphocytes
dc.subject.enNK cells
dc.subject.enNKT-like cells
dc.subject.enPDAC
dc.subject.enPancreatic ductal adenocarcinoma
dc.subject.enT cells
dc.subject.enT regulatory cells
dc.subject.encytotoxic T cells
dc.subject.engemcitabine
dc.subject.enmFOLFIRINOX
dc.subject.ensurgery
dcterms.sourcetitleAnticancer research
dc.description.issueiss. 6
dc.description.volumevol. 42
dc.publisher.nameInternational Institute of Anticancer Research
dc.publisher.cityAthens
dc.identifier.doi35641268
dc.identifier.doi000809739000016
dc.identifier.doi10.21873/anticanres.15794
dc.identifier.elaba134703560


Files in this item

Thumbnail
Name:
3067.full.pdf
Size:
326.3Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record